Kyverna Therapeutics, Inc. Research and Development Expense
Kyverna Therapeutics, Inc. (KYTX) reported Research and Development Expense of $24.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Kyverna Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $24.79M, a 30.79% decline year-over-year.
- Kyverna Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $30.07M, a 19.66% decline year-over-year.
- Kyverna Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $30.01M, a 10.36% decline year-over-year.
- Kyverna Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $30.46M, a 4.33% increase year-over-year.
- Kyverna Therapeutics, Inc. research and development expense for fiscal 2025 was $133.72M, a 18.89% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. research and development expense for fiscal 2024 was $112.47M, a 125.29% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. research and development expense for fiscal 2023 was $49.92M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.79M 10-Q · filed 2026-08-11 | $54.86M 10-Q · filed 2026-08-11 | $84.88M derived: sum of 3 quarters · filed 2026-08-11 | $115.33M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $30.07M 10-Q · filed 2026-05-12 | $60.09M derived: sum of 2 quarters · filed 2026-05-12 | $90.54M derived: sum of 3 quarters · filed 2026-05-12 | $126.36M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $30.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $60.47M derived: sum of 2 quarters · filed 2026-03-26 | $96.29M derived: sum of 3 quarters · filed 2026-08-11 | $133.72M 10-K · filed 2026-03-26 |
| 2025-09-30 | $30.46M 10-Q · filed 2025-11-12 | $66.27M derived: sum of 2 quarters · filed 2026-08-11 | $103.71M 10-Q · filed 2025-11-12 | $137.19M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $35.82M 10-Q · filed 2026-08-11 | $73.25M 10-Q · filed 2026-08-11 | $106.73M derived: sum of 3 quarters · filed 2026-08-11 | $135.93M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $37.43M 10-Q · filed 2026-05-12 | $70.92M derived: sum of 2 quarters · filed 2026-05-12 | $100.11M derived: sum of 3 quarters · filed 2026-05-12 | $127.43M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $33.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $62.68M derived: sum of 2 quarters · filed 2026-03-26 | $90.00M derived: sum of 3 quarters · filed 2026-03-26 | $112.47M 10-K · filed 2026-03-26 |
| 2024-09-30 | $29.19M 10-Q · filed 2025-11-12 | $56.51M derived: sum of 2 quarters · filed 2025-11-12 | $78.99M 10-Q · filed 2025-11-12 | $96.15M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $27.32M 10-Q · filed 2025-08-12 | $49.80M 10-Q · filed 2025-08-12 | $66.96M derived: sum of 3 quarters · filed 2025-08-12 | $80.60M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $22.48M 10-Q · filed 2025-05-13 | $39.64M derived: sum of 2 quarters · filed 2025-05-13 | $53.28M derived: sum of 3 quarters · filed 2025-05-13 | $63.69M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $17.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $30.81M derived: sum of 2 quarters · filed 2025-03-27 | $41.21M derived: sum of 3 quarters · filed 2025-03-27 | $49.92M 10-K · filed 2025-03-27 |
| 2023-09-30 | $13.64M 10-Q · filed 2024-11-13 | $24.05M derived: sum of 2 quarters · filed 2024-11-13 | $32.76M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $10.40M 10-Q · filed 2024-08-12 | $19.12M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $8.71M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |